Stephen Gunnion, CEO, RELIEF THERAPEUTICS Holding 00:00:00
Relief Therapeutics CEO Jack Weinstein tells Proactive's Stephen Gunnion that a reverse 1-for-400 stock split has taken effect at the company as it targets a listing on the Nasdaq in a move that will raise its profile and attract more institutional investors.